Status:
COMPLETED
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Medivation, Inc.
Conditions:
Alzheimer's Disease
Huntington's Disease
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
Detailed Description
The main purpose for this study is to determine whether dimebon exhibits abuse potential.
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 18 and 55 years.
- Recreational polydrug user with a history of CNS depressant use.
Exclusion
- History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee.
- A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines.
- Self-reported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSM-IV-TR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation).
- History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00975481
Start Date
October 1 2009
End Date
February 1 2010
Last Update
April 2 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.